Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| GRAN | Grande Group | $2.29 | $0.27 | 1336.63% | 151 | $57.0M | $1.81$6.70 |
| CEP | Cantor Equity Partners | $16.17 | $4.33 | 36.57% | 183.1K | $151.6M | $10.22$59.75 |
| CVKD | Cadrenal Therapeutics | $10.46 | $1.60 | 18.06% | 22.9K | $18.4M | $8.12$22.90 |
| GNPX | Genprex | $3.33 | $0.50 | 17.67% | 332.9K | $6.6M | $2.61$63.00 |
| UPC | Universe Pharmaceuticals Inc | $4.15 | $0.62 | 17.56% | 432.8K | $2.0M | $2.51$197.20 |
| MDCX | Medicus Pharma | $2.02 | $0.29 | 16.76% | 175.8K | $20.4M | $1.68$8.94 |
| PATH | UiPath | $17.31 | $2.45 | 16.45% | 1.7M | $7.9B | $9.38$18.74 |
| TIVC | Tivic Health Systems | $2.05 | $0.28 | 15.82% | 59K | $3.1M | $1.47$15.64 |
| WRAP | Wrap Technologies | $2.35 | $0.32 | 15.76% | 262.2K | $104.6M | $1.20$3.00 |
| SAIC | Science Applications International | $101.23 | $13.70 | 15.65% | 422.9K | $4.0B | $84.16$133.00 |
Related Articles
Featured Article
Could This Quiet AI Company Become the Next Big Winner?
Leo Sun|Dec 2, 2025
UiPath still trades 75% below its IPO price.
Should You Buy UiPath Stock Before the Huge Investor Update?
Parkev Tatevosian, CFA|Dec 1, 2025
UiPath stands at the crossroads of automation and artificial intelligence.
Consumers Are Struggling. Could Buying This Dollar-Store Stock Be a Brilliant Move?
Jeremy Bowman|Nov 14, 2025
Challenges to consumer spending are mounting. Here's what that means for investors.
Advertisement
2 Top Bargain Stocks Ready for a Bull Run
Geoffrey Seiler|Nov 9, 2025
UiPath and GitLab are two bargain tech stocks with big potential.
Why UiPath Jumped 19% in October
Jeremy Bowman|Nov 7, 2025
Its annual Fusion conference helped give the stock a boost.
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
James Brumley|Nov 5, 2025
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.
How UiPath Is Positioning Its AI Strategy for the Next Decade
Lawrence Nga|Oct 30, 2025
UiPath isn't just riding the AI wave -- it's quietly building the infrastructure beneath it.
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
Prosper Junior Bakiny|Oct 29, 2025
This stock has caught fire after some recent events, but how long will that last?
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
Cory Renauer|Oct 26, 2025
The clinical-stage biotech is working on a new type of weight management drug.
4 Major Trends Powering UiPath's Next Growth Phase
Lawrence Nga|Oct 26, 2025
For long-term investors looking to ride the wave of AI-powered productivity, UiPath might just be one of the more underappreciated names worth watching closely.
